Canada markets closed

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.25000.0000 (0.00%)
At close: 03:55PM EDT
Full screen
Previous Close0.2500
Bid0.2500 x 0
Ask0.2550 x 0
Day's Range0.2500 - 0.2800
52 Week Range0.2200 - 0.9000
Avg. Volume64,046
Market Cap62.254M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

    CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffrey125,007,1427,

  • GlobeNewswire

    Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

    CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the journal Biomedicine & Pharmacotherapy. The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective B

  • GlobeNewswire

    Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

    CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients. The meeting is scheduled for early August. In response to the transformation of the COVID-19 pandemic, advancement to the Pha